TY  - BOOK
AU  - Pratt, William B.
AU  - Ruddon, Raymond W. ;Ensminger, William D. ;Maybaum, Jonathan 
TI  - The anticancer drugs
SN  - 9780195067385
AV  - RC 271.C5 .P73 1994 
PY  - 1994///
CY  - New York
PB  - Oxford University Press
KW  - CANCER -- CHEMOTHERAPY
N1  - Includes bibliographical references and index; Principles of cancer chemotherapy -- Cancer problem -- Some milestones in the development of cancer chemotherapy -- Determinants of drug responsivveness -- Resistance to anticancer drugs -- Anticancer drugs -- Antimetabolites -- Folate antagonists, pyrimidine antagonists, purine antagonists, sugar-modified analogs, ribonucleotide reductase inhibitors -- Covalent DNA binding drugs -- Nitrogen mustards, aziridines, alkane sulfonates, nitrosoureas, platinum compounds, monoalkylating agents -- Noncovalent DNA binding drugs -- Antrhacyclines, mitoxantrone, dactinomycin, bleomycin, plicamycin -- Inhibitors of chromatin function -- Topoisomerase inhibitors, microtubule inhibitors -- Drugs affecting endocrine function -- Glucocorticoids, estrogens, antiestrogens, progestins, androgens, antiandrogens, LHRH (GnRH) agonists, aromatase inhibitors, adrenocortical suppressors -- Clinical cancer chemotherapy -- Choice of drugs for cancer chemotherapy -- Cancer treatment.  (cont) New directions in cancer chemotherapy -- Anticancer drug development -- Biological treatments of cancer -- Potential targets for new anticancer drugs
N2  - This is an up-to-date review of the pharmacology, mechanisms of action, development of resistance, and toxicity of cancer chemotherapeutic agents. A rationale for their clinical use, based on cancer cell biology, is given for each class of drugs
ER  -